NCT00595426

Brief Summary

To evaluate the safety and efficacy of twice daily dosing and once daily dosing of YM150 in subjects undergoing primary elective knee replacement surgery

Trial Health

90
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
685

participants targeted

Target at P75+ for phase_2

Timeline
Completed

Started May 2008

Shorter than P25 for phase_2

Geographic Reach
2 countries

54 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 7, 2008

Completed
9 days until next milestone

First Posted

Study publicly available on registry

January 16, 2008

Completed
4 months until next milestone

Study Start

First participant enrolled

May 1, 2008

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2009

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2009

Completed
Last Updated

March 25, 2013

Status Verified

May 1, 2010

Enrollment Period

1 year

First QC Date

January 7, 2008

Last Update Submit

March 19, 2013

Conditions

Keywords

Knee ArthroplastyFactor XaVTEThrombosisAnticoagulants

Outcome Measures

Primary Outcomes (2)

  • The incidence of total venous thromboembolisms (VTE).

    6 Weeks

  • The incidence of bleeding events classified as major by the Adjudication Committee

    6 Weeks

Secondary Outcomes (2)

  • Evaluation of efficacy variables including: Proximal VTE, Distal VTE, Confirmed symptomatic VTE, death due to any cause

    6 Weeks

  • Incidence of the bleeding types: major, clinically relevant nonmajor, minor

    6 Weeks

Study Arms (5)

1. YM150 Dose X, twice daily

EXPERIMENTAL
Drug: YM150

2. YM150 Dose Y, once daily

EXPERIMENTAL
Drug: YM150

3. YM150 Dose Y, twice daily

EXPERIMENTAL
Drug: YM150

4. YM150 Dose Z, once daily

EXPERIMENTAL
Drug: YM150

5. Warfarin

ACTIVE COMPARATOR

various doses

Drug: Warfarin

Interventions

YM150DRUG

Oral

1. YM150 Dose X, twice daily2. YM150 Dose Y, once daily3. YM150 Dose Y, twice daily4. YM150 Dose Z, once daily

Oral

5. Warfarin

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Subject is scheduled for elective primary knee arthroplasty
  • Written Informed consent obtained

You may not qualify if:

  • Subject has documented history of previous VTE
  • Subject is considered to be at increased risk of VTE
  • Subject has active bleeding or any condition associated with increased risk of bleeding
  • Subject is planning to have surgery on the contralateral knee at the same time or within 6 weeks after enrollment into the study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (54)

Unknown Facility

Mobile, Alabama, 36608, United States

Location

Unknown Facility

Phoenix, Arizona, 85023, United States

Location

Unknown Facility

Tuscon, Arizona, 85712, United States

Location

Unknown Facility

Little Rock, Arkansas, 72205, United States

Location

Unknown Facility

Fountain Valley, California, 92708, United States

Location

Unknown Facility

La Mesa, California, 91942, United States

Location

Unknown Facility

Long Beach, California, 90806, United States

Location

Unknown Facility

Long Beach, California, 90822, United States

Location

Unknown Facility

San Diego, California, 92128, United States

Location

Unknown Facility

Santa Ana, California, 92074, United States

Location

Unknown Facility

Torrance, California, 90502, United States

Location

Unknown Facility

Yuba City, California, 95991, United States

Location

Unknown Facility

Aurora, Colorado, 80012, United States

Location

Unknown Facility

Denver, Colorado, 80230, United States

Location

Unknown Facility

Lone Tree, Colorado, 80124, United States

Location

Unknown Facility

Washington D.C., District of Columbia, 20017, United States

Location

Unknown Facility

Bay Pines, Florida, 33744, United States

Location

Unknown Facility

Bradenton, Florida, 34209, United States

Location

Unknown Facility

Gulf Breeze, Florida, 32561, United States

Location

Unknown Facility

Hollywood, Florida, 33021, United States

Location

Unknown Facility

St. Petersburg, Florida, 33703, United States

Location

Unknown Facility

St. Petersburg, Florida, 33713, United States

Location

Unknown Facility

Decatur, Georgia, 30033, United States

Location

Unknown Facility

Savannah, Georgia, 31405, United States

Location

Unknown Facility

Boise, Idaho, 83702, United States

Location

Unknown Facility

Idaho Falls, Idaho, 83404, United States

Location

Unknown Facility

Springfield, Illinois, 62703, United States

Location

Unknown Facility

Springfield, Illinois, 62794, United States

Location

Unknown Facility

Baltimore, Maryland, 21218, United States

Location

Unknown Facility

Cincinnati, Ohio, 45242, United States

Location

Unknown Facility

Cleveland, Ohio, 44195, United States

Location

Unknown Facility

Tulsa, Oklahoma, 74146, United States

Location

Unknown Facility

Charleston, South Carolina, 29414, United States

Location

Unknown Facility

Austin, Texas, 78745, United States

Location

Unknown Facility

Dallas, Texas, 75231, United States

Location

Unknown Facility

Grapevine, Texas, 76051, United States

Location

Unknown Facility

Houston, Texas, 77030, United States

Location

Unknown Facility

Lubbock, Texas, 79410, United States

Location

Unknown Facility

Lubbock, Texas, 79412, United States

Location

Unknown Facility

Odessa, Texas, 79761, United States

Location

Unknown Facility

San Antonio, Texas, 78217, United States

Location

Unknown Facility

San Antonio, Texas, 78229, United States

Location

Unknown Facility

Richmond, Virginia, 23249, United States

Location

Unknown Facility

Richmond, Virginia, 23294, United States

Location

Unknown Facility

Red Deer, Alberta, T4N 4E7, Canada

Location

Unknown Facility

Ajax, Ontario, L1S 2J5, Canada

Location

Unknown Facility

Burlington, Ontario, L7R 4B7, Canada

Location

Unknown Facility

Montreal, Ontario, H1T 2M4, Canada

Location

Unknown Facility

Newmarket, Ontario, L3Y 2P9, Canada

Location

Unknown Facility

Saint Catherines, Ontario, L2R 7P3, Canada

Location

Unknown Facility

Scarborough Village, Ontario, M1E 5E9, Canada

Location

Unknown Facility

Thunder Bay, Ontario, P7B 6V4, Canada

Location

Unknown Facility

Waterloo, Ontario, N2J 1CA, Canada

Location

Unknown Facility

Charlottetown, Prince Edward Island, C1A 1L2, Canada

Location

MeSH Terms

Conditions

Thrombosis

Interventions

Warfarin

Condition Hierarchy (Ancestors)

Embolism and ThrombosisVascular DiseasesCardiovascular Diseases

Intervention Hierarchy (Ancestors)

4-HydroxycoumarinsCoumarinsBenzopyransPyransHeterocyclic Compounds, 1-RingHeterocyclic CompoundsHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-Ring

Study Officials

  • Central Contact

    Astellas Pharma Global Development

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 7, 2008

First Posted

January 16, 2008

Study Start

May 1, 2008

Primary Completion

May 1, 2009

Study Completion

May 1, 2009

Last Updated

March 25, 2013

Record last verified: 2010-05

Locations